Skip to main content

Table 2 US FDA-approved targeted therapies for ovarian cancer

From: Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

  Drug class Ovarian cancer indication Black box warnings Warnings and precautions
Bevacizumab [33] VEGF inhibitor; anti-angiogenesis Platinum-resistant recurrent disease
• In combination with paclitaxel, PLD, or topotecan with no more than 2 prior lines of chemotherapy
Platinum-sensitive recurrent disease
• In combination with carboplatin and paclitaxel, or carboplatin and gemcitabine; followed by single-agent bevacizumab
• Gastrointestinal perforations
• Surgery and wound healing complications
• Hemorrhage
• Perforation or fistula
• Arterial and venous thromboembolic events
• Hypertension
• Posterior reversible encephalopathy syndrome
• Proteinuria
• Infusion reactions
• Embryo-fetal toxicity
• Ovarian failure
Niraparib [36] PARP inhibitor Maintenance treatment of recurrent disease in complete or partial response to platinum-based chemotherapy None • Myelodysplastic syndrome/acute myeloid leukemia
• Bone marrow suppression
• Cardiovascular effects (blood pressure and heart rate)
• Embryo-fetal toxicity
Olaparib [35] PARP inhibitor Maintenance treatment of recurrent disease in complete or partial response to platinum-based chemotherapy
Treatment of deleterious or suspected deleterious germline BRCA-mutated disease with ≥3 prior lines of chemotherapy; requires FDA-approved companion diagnostic test
None • Myelodysplastic syndrome/acute myeloid leukemia
• Pneumonitis
• Embryo-fetal toxicity
Rucaparib [34] PARP inhibitor Monotherapy in patients with deleterious BRCA mutations treated with two or more prior chemotherapies; requires companion diagnostic test None • Myelodysplastic syndrome/acute myeloid leukemia
• Embryo-fetal toxicity
  1. PARP poly (ADP-ribose) polymerase, PLD pegylated liposomal doxorubicin, VEGF vascular endothelial growth factor